Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy

Abstract

Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (P = .016), FEV1 ≥ 2L (P = .03), and the use of platinum/docetaxel (P < .0001) were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies.

Trend Analysis of Lung Cancer Incidence Rates in Ninawa Province, Iraq, from 2000 to 2010 - Decrease and Recent Stability

“…It's higher than that observed in overall Iraq, GCC countries, USA and Australia. The proportion of Large cell: *Computed by the authors; Data from (AlMadouj et al, 2011); ** Computed by the authors; Data from (Abbasi and Badheeb, 2010) Carcinoma (11.61%), lower than that observed in Egypt and Australia, higher than that observed in overall Iraq, GCC countries, Jordan and UAS. The proportion of adenocarcinoma (6.79%), lower than proportion of overall Iraq, and several Arab and developed countries such as, GCC countries, Egypt, Jordan, Australia and USA.…”

Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study

“…Also, consistent with prior studies, female sex (P = .05; OR, 0.41) predicted improved outcomes. 3,16,17 We performed a matched cohort comparison of these patients to a subset of stage IV patients who received chemotherapy alone and identified the patients who received definitive thoracic radiation therapy as having improved local control and overall survival compared with patients who did not. However, there are several weaknesses to such an analysis, including selection bias and the potential impact of confounders.…”

Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer

“…3,10,11 In previous studies, it has been clearly demonstrated that MPV is associated with systemic inflammation as well as thromboembolism. 3,10,11 In previous studies, it has been clearly demonstrated that MPV is associated with systemic inflammation as well as thromboembolism.…”

“…Many prognostic factors have been determined to estimate for clinical course in patients with NSCLC but majority of the defined prognostic factors in NSCLC have been not used in clinical practice yet. 3,10,11 In previous studies, it has been clearly demonstrated that MPV is associated with systemic inflammation as well as thromboembolism. 6,8,10 Some studies have reported a relationship between increased MPV in cardiovascular and cerebrovascular diseases, in which systemic inflammation has an effect on disease prognosis and severity.…”